Samuel George A. III 4

What Happened

• Samuel George A. III, General Counsel and Secretary of Lineage Cell Therapeutics (LCTX), had 6,075 restricted stock units (RSUs vest) convert into 6,075 common shares on February 11, 2026.
• To satisfy statutory tax withholding, the company withheld 2,502 of those shares at a withholding value of $1.80 per share (total $4,504). No shares were sold on the open market in connection with this transaction.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (timely within the two-business-day window).
• Vesting/conversion: 6,075 RSUs converted one-for-one into common shares (reported as derivative conversion/exercise).
• Tax withholding: 2,502 shares withheld at $1.80/share for $4,504 (reported as disposition to cover tax liability).
• Shares owned after the transaction: not disclosed in the filing.
• Relevant footnotes: these RSUs were part of a 24,303-RSU grant made Feb 11, 2022 that vests ~25% each year through 2026; the filing notes the withholding was done by the issuer and no open-market sale occurred.

Context

• This is a routine vesting/tax-withholding event, not an open-market sale or purchase. For RSU vesting, companies often withhold shares to cover taxes (a tax-withholding disposition) rather than selling shares on the market. Such transactions reflect compensation vesting rather than a signal of insider buying or selling intent.